SI3085386T1 - Metoda zaviranja resorpcije kosti - Google Patents

Metoda zaviranja resorpcije kosti

Info

Publication number: SI3085386T1
Authority: SI; Slovenia
Prior art keywords: bone resorption; inhibiting bone; inhibiting; resorption; bone
Prior art date: 2007-09-17

Application number

SI200832137T

Other languages

English (en)

Inventor

Ian Desmond Padhi

Graham Richard Jang

Original Assignee

Amgen Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-17

Filing date

2008-09-17

Publication date

2020-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40371592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3085386(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-09-17 Application filed by Amgen Inc. filed Critical Amgen Inc.

2020-11-30 Publication of SI3085386T1 publication Critical patent/SI3085386T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Emergency Medicine (AREA)

SI200832137T 2007-09-17 2008-09-17 Metoda zaviranja resorpcije kosti SI3085386T1 (sl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97302407P	2007-09-17	2007-09-17
EP16162068.7A EP3085386B1 (en)	2007-09-17	2008-09-17	Method for inhibiting bone resorption

Publications (1)

Publication Number	Publication Date
SI3085386T1 true SI3085386T1 (sl)	2020-11-30

Family

ID=40371592

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
SI200832137T SI3085386T1 (sl)	2007-09-17	2008-09-17	Metoda zaviranja resorpcije kosti
SI200831170T SI2195026T1 (sl)	2007-09-17	2008-09-17	Protitelesa proti sklerostinu
SI200831663A SI2556841T1 (sl)	2007-09-17	2008-09-17	Postopek za inhibiranje kostne resorpcije
SI200832217T SI3725329T1 (sl)	2007-09-17	2008-09-17	Postopek zaviranja resorpcije kosti

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
SI200831170T SI2195026T1 (sl)	2007-09-17	2008-09-17	Protitelesa proti sklerostinu
SI200831663A SI2556841T1 (sl)	2007-09-17	2008-09-17	Postopek za inhibiranje kostne resorpcije
SI200832217T SI3725329T1 (sl)	2007-09-17	2008-09-17	Postopek zaviranja resorpcije kosti

Country Status (21)

Country	Link
US (7)	US8017120B2 (sl)
EP (5)	EP3085386B1 (sl)
JP (2)	JP5643094B2 (sl)
AR (2)	AR068471A1 (sl)
AU (1)	AU2008302313C1 (sl)
CA (2)	CA2699905C (sl)
CL (1)	CL2008002775A1 (sl)
CY (3)	CY1114961T1 (sl)
DK (4)	DK3725329T3 (sl)
ES (4)	ES2445792T3 (sl)
FI (1)	FI3725329T3 (sl)
HK (1)	HK1182017A1 (sl)
HR (4)	HRP20240493T3 (sl)
HU (3)	HUE066466T2 (sl)
LT (3)	LT3085386T (sl)
MX (1)	MX2010002971A (sl)
PL (4)	PL3085386T3 (sl)
PT (4)	PT3085386T (sl)
SI (4)	SI3085386T1 (sl)
TW (2)	TWI612972B (sl)
WO (1)	WO2009039175A2 (sl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ512122A (en)	1998-11-27	2003-12-19	Darwin Discovery Ltd	Compositions and methods for increasing bone mineralization
WO2005014650A2 (en)	2003-06-16	2005-02-17	Celltech R & D, Inc.	Antibodies specific for sclerostin and methods for increasing bone mineralization
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
EP2460828A3 (en) *	2006-11-10	2012-08-08	UCB Pharma, S.A.	Antibodies and diagnostics
WO2008061013A2 (en) *	2006-11-10	2008-05-22	Amgen Inc.	Antibody-based diagnostics and therapeutics
US8178099B2 (en)	2006-12-29	2012-05-15	Osteogenex Inc.	Methods of altering bone growth by administration of sost or wise antagonist or agonist
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es)	2007-10-12	2009-12-02	Novartis Ag	Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
WO2009062152A1 (en) *	2007-11-09	2009-05-14	Washington University In St. Louis	Methods for measuring the metabolism of cns derived biomolecules in vivo
BRPI0819688A2 (pt) *	2007-12-14	2015-06-16	Amgen Inc	Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
BRPI0911431B8 (pt)	2008-04-11	2021-05-25	Chugai Pharmaceutical Co Ltd	composição farmacêutica compreendendo um antígeno e método para aumentar o número de antígenos que podem ser ligados por um anticorpo
SMT202000095T1 (it)	2010-05-14	2020-03-13	Amgen Inc	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
EP3912640B1 (en)	2010-11-05	2025-03-05	Novartis AG	Pharmaceutical compositions comprising secukinumab
JP6030452B2 (ja)	2010-11-30	2016-11-24	中外製薬株式会社	複数分子の抗原に繰り返し結合する抗原結合分子
AU2011336360A1 (en) *	2010-12-02	2013-07-04	The Washington University	Compositions and methods for treating amyloid plaque associated symptoms
CA2828000A1 (en)	2011-03-01	2012-09-07	Amgen Inc.	Bispecific binding agents
CR20160147A (es)	2011-03-25	2016-08-03	Amgen Inc	Formulaciones de anticuerpos
ES2685479T3 (es) *	2011-04-19	2018-10-09	Amgen Inc.	Método para el tratamiento de la osteoporosis
JP2014515759A (ja)	2011-04-29	2014-07-03	ノバルティスアーゲー	扁平上皮がんを治療する方法関連出願
DK2739311T3 (en) *	2011-08-04	2018-04-23	Amgen Inc	Method of treating bone slit defects
WO2013043840A1 (en) *	2011-09-22	2013-03-28	Exelixis, Inc.	Method for treating osteoporosis
CN107126560A (zh)	2011-12-28	2017-09-05	安进公司	通过使用抗骨硬化蛋白抗体治疗牙槽骨流失的方法
EP3626267A1 (en)	2012-07-05	2020-03-25	UCB Pharma, S.A.	Treatment for bone diseases
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
WO2014118705A1 (en)	2013-01-31	2014-08-07	Novartis Ag	Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
WO2014155278A2 (en)	2013-03-26	2014-10-02	Novartis Ag	Methods of treating autoimmune diseases using il-17 antagonists
CA2962969C (en)	2014-09-30	2023-03-21	Washington University	Tau kinetic measurements
MA41142A (fr)	2014-12-12	2017-10-17	Amgen Inc	Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
GB201604124D0 (en)	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
US10961305B2 (en)	2016-12-21	2021-03-30	Mereo Biopharma 3 Limited	Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CN117442720A (zh)	2016-12-21	2024-01-26	美莱奥生物制药第三有限公司	抗硬化蛋白抗体在治疗成骨不全症中的用途
US11608374B2 (en)	2017-01-30	2023-03-21	Chugai Seiyaku Kabushiki Kaisha	Anti-sclerostin antibodies and methods of use
CN119241705A (zh) *	2018-03-30	2025-01-03	安姆根有限公司	C末端抗体变体
GB201810746D0 (en)	2018-06-29	2018-08-15	Mereo Biopharma 3 Ltd	Use of sclerostin antagonist
CN111658821A (zh) *	2020-06-03	2020-09-15	深圳市百吉因生物科技有限公司	负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用
WO2024129988A1 (en)	2022-12-14	2024-06-20	Flagship Pioneering Innovations Vii, Llc	Compositions and methods for delivery of therapeutic agents to bone
WO2025000015A1 (en) *	2023-06-27	2025-01-02	Perron Institute for Neurological and Translational Science Limited	Antisense oligomer treatment for bone loss

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4331647A (en) *	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) *	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4411993A (en) *	1981-04-29	1983-10-25	Steven Gillis	Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) *	1981-10-19	1984-01-24	Laipply Thomas C	One piece alcohol preparation device
USRE32011E (en) *	1981-12-14	1985-10-22	Scripps Clinic And Research Foundation	Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) *	1982-12-13	1985-09-24	Massachusetts Institute Of Technology	Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en) *	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) *	1984-05-11	1986-01-09	Matter + Siegmann Ag, Wohlen	Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) *	1984-12-03	1990-02-20	Teijin Limited	Monoclonal antibody to human protein C
US4987071A (en)	1986-12-03	1991-01-22	University Patents, Inc.	RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
DE3852539T3 (de)	1987-12-15	2005-08-04	Gene Shears Pty. Ltd.	Ribozyme.
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5571714A (en)	1988-12-22	1996-11-05	Celtrix Pharmaceuticals, Inc.	Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5549910A (en) *	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
US5244805A (en)	1989-05-17	1993-09-14	University Of Georgia Research Foundation, Inc.	Baculovirus expression vectors
US5177197A (en)	1990-02-27	1993-01-05	Ludwig Institute For Cancer Research	Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) *	1990-04-03	1995-11-14	Ciba-Geigy Corporation	Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
JP3218637B2 (ja) *	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
CA2090126C (en) *	1990-08-02	2002-10-22	John W. Schrader	Methods for the production of proteins with a desired function
JP2958076B2 (ja) *	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) *	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) *	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
JPH04141095A (ja)	1990-10-02	1992-05-14	Chemo Sero Therapeut Res Inst	組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) *	1990-10-12	1991-12-03	Trustees Of The University Of Pennsylvania	Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
EP0554376A4 (en)	1990-10-22	1994-08-24	Fox Chase Cancer Center	Dna construct for providing rna therapy
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5399363A (en) *	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
KR100249937B1 (ko)	1991-04-25	2000-04-01	나가야마 오사무	인간 인터루킨-6 수용체에 대한 재구성 인간 항체
US5807683A (en)	1992-11-19	1998-09-15	Combichem, Inc.	Combinatorial libraries and methods for their use
CA2164505A1 (en) *	1993-06-07	1994-12-22	Phillip W. Berman	Hiv envelope polypeptides
US5543158A (en)	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
US5453492A (en) *	1993-07-28	1995-09-26	La Jolla Cancer Research Foundation	60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5837458A (en) *	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5605793A (en) *	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
JPH10511840A (ja)	1994-04-29	1998-11-17	クリエイティブバイオモレキュールズ，インコーポレイテッド	形態形成タンパク質特異細胞表面レセプターおよびその使用
US5738996A (en)	1994-06-15	1998-04-14	Pence, Inc.	Combinational library composition and method
DE4427221A1 (de)	1994-08-01	1996-02-08	Gsf Forschungszentrum Umwelt	Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en)	1994-11-22	1998-12-08	Genetics Institute, Inc.	DNA molecules encoding human chordin
US6057421A (en) *	1994-11-30	2000-05-02	Immpheron, Inc.	Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5723750A (en)	1995-01-12	1998-03-03	Vanderbilt University	Transgenic plants expressing disassembly deficient viral coat proteins
US5795587A (en) *	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en)	1995-04-04	1998-07-29	Elan Corp Plc	Controlled release biodegradable nanoparticles containing insulin
CA2220912A1 (en) *	1995-06-05	1996-12-12	Gregg A. Hastings	Human ccn-like growth factor
US5738868A (en) *	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
JP4124486B2 (ja) *	1996-05-22	2008-07-23	ビベンティアバイオテックインコーポレイテッド	ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用
US6133426A (en) *	1997-02-21	2000-10-17	Genentech, Inc.	Humanized anti-IL-8 monoclonal antibodies
US5989909A (en)	1997-09-26	1999-11-23	Millennium Biotherapeutics, Inc.	Huchordin and uses thereof
US6117911A (en) *	1997-04-11	2000-09-12	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6278039B1 (en)	1997-05-28	2001-08-21	Axys Pharmaceuticals, Inc.	C. elegans deletion mutants
WO1998056915A2 (en)	1997-06-12	1998-12-17	Research Corporation Technologies, Inc.	Artificial antibody polypeptides
US6075007A (en)	1997-07-17	2000-06-13	Regeneron Pharmaceuticals, Inc.	Modified noggin polypeptide and compositions
CA2297109A1 (en)	1997-08-01	1999-02-11	Genset	5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en) *	1997-09-08	2004-11-09	The Public Health Research Institute Of The City Of New York, Inc.	HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6251588B1 (en)	1998-02-10	2001-06-26	Agilent Technologies, Inc.	Method for evaluating oligonucleotide probe sequences
GB9818881D0 (en) *	1998-08-28	1998-10-21	Glaxo Group Ltd	Compounds
US6544485B1 (en) *	2001-01-29	2003-04-08	Sharper Image Corporation	Electro-kinetic device with enhanced anti-microorganism capability
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
NZ512122A (en)	1998-11-27	2003-12-19	Darwin Discovery Ltd	Compositions and methods for increasing bone mineralization
JP2002536968A (ja)	1999-01-29	2002-11-05	イムクローンシステムズインコーポレイティド	Ｋｄｒに特異的な抗体およびその使用
US6110462A (en)	1999-03-03	2000-08-29	The Scripps Research Institute	Enzymatic DNA molecules that contain modified nucleotides
AU4851900A (en)	1999-06-09	2000-12-28	Genentech Inc.	Compositions and methods for the treatment of tumor
US6197592B1 (en) *	1999-07-15	2001-03-06	Bio-Rad Laboratories, Inc.	Clinical control materials for detection of bone resorptive markers
CA2401175A1 (en)	2000-03-02	2001-09-07	Amgen, Inc.	Chordin-like-2 molecules and uses thereof
MXPA02011808A (es) *	2000-06-01	2003-04-10	Amgen Inc	Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos.
AU2001272482A1 (en)	2000-06-19	2002-01-02	F.Hoffmann-La Roche Ag	Osteolevin gene polymorphisms
CA2632702A1 (en)	2000-09-01	2002-03-28	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2332402T5 (es)	2000-10-12	2018-05-14	Genentech, Inc.	Formulaciones de proteína concentradas de viscosidad reducida
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) *	2001-03-13	2002-09-13	The Minister Of National Defence	Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
DE10145772A1 (de) *	2001-09-17	2003-04-10	Bayer Cropscience Ag	DELTA·1·-Pyrroline
US7261892B2 (en)	2001-11-27	2007-08-28	Celltech R&D Limited	Methods for diagnosis and treatment of epithelial-derived cancers
JP4467304B2 (ja)	2001-12-06	2010-05-26	バイオコントロールシステムズ，インコーポレイティド	サンプル収集および試験システム
US20030186915A1 (en) *	2002-02-11	2003-10-02	Yang Pan	Regulatory polynucleotides and uses thereof
EP2277522B1 (en)	2002-03-01	2012-11-21	UCB Manufacturing, Inc.	Methods for increasing or decreasing bone density and identifying molecules
AU2003221841A1 (en)	2002-04-03	2003-10-27	Celltech R And D, Inc.	Association of polymorphisms in the sost gene region with bone mineral density
FR2838379B1 (fr)	2002-04-12	2005-06-24	Valeo Climatisation	Dispositif de purification de l'air de l'habitacle d'un vehicule automobile
AU2003276430A1 (en) *	2002-06-14	2003-12-31	Stowers Institute For Medical Research	Wise/sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) *	2003-06-16	2011-02-22	Stowers Institute For Medical Research	Antibodies that specifically bind SOST peptides
WO2004098491A2 (en)	2002-11-01	2004-11-18	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
PT2284266E (pt)	2002-11-14	2013-12-17	Thermo Fisher Scient Biosciences Inc	Siarn contra tp53
DE10255152A1 (de)	2002-11-26	2004-06-03	Von Langen Ursula Lang	Schadstoffsauger
US7642238B2 (en) *	2002-12-05	2010-01-05	Shaughnessy John D	Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) *	2003-01-15	2004-07-22	Rajiv Doshi	System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
SI1608399T1 (sl)	2003-03-14	2012-05-31	Usb Mfg Inc A Company Inc Under The Laws Of The State Of Delaware	Kompleks sklerostina in noggina ali chordina in sredstva ki modulirajo tvorbo navedenega kompleksa
JP4605799B2 (ja)	2003-04-02	2011-01-05	ダーマコン，インコーポレイテッド	Ｒｎａ干渉において使用するための修飾ポリヌクレオチド
US20050158303A1 (en)	2003-04-04	2005-07-21	Genentech, Inc.	Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es)	2003-04-23	2009-08-04	Centro Inmunologia Molecular	Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
WO2005014650A2 (en)	2003-06-16	2005-02-17	Celltech R & D, Inc.	Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en)	2003-09-22	2013-06-11	University Of Connecticut	Sclerostin and the inhibition of WNT signaling and bone formation
ATE447024T1 (de)	2004-02-06	2009-11-15	Dharmacon Inc	Stabilisierte rnas als transfektionskontrollen und silencing-reagentien
KR101147147B1 (ko)	2004-04-01	2012-05-25	머크 샤프 앤드 돔 코포레이션	Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US20050267233A1 (en)	2004-05-25	2005-12-01	Joshi Ashok V	Anti-microbial handle system
CA2574881C (en)	2004-08-04	2013-01-08	Amgen Inc.	Antibodies to dkk-1
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
US8541177B2 (en) *	2006-01-13	2013-09-24	A Chan Holding B.V.	Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
WO2008061013A2 (en)	2006-11-10	2008-05-22	Amgen Inc.	Antibody-based diagnostics and therapeutics
EP2460828A3 (en)	2006-11-10	2012-08-08	UCB Pharma, S.A.	Antibodies and diagnostics
US20080120672A1 (en)	2006-11-21	2008-05-22	Francesco Caggioni	Methods and Apparatus for Weighted Multicasting of Data Streams
US8178099B2 (en)	2006-12-29	2012-05-15	Osteogenex Inc.	Methods of altering bone growth by administration of sost or wise antagonist or agonist
MX2009008096A (es)	2007-02-02	2009-08-07	Novartis Ag	Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos.
JP2010524846A (ja)	2007-03-20	2010-07-22	イーライリリーアンドカンパニー	抗スクレロスチン抗体
JOP20080381B1 (ar)	2007-08-23	2023-03-28	Amgen Inc	بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es)	2007-10-12	2009-12-02	Novartis Ag	Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EP2209491B1 (en)	2007-11-02	2015-10-28	Novartis AG	Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
BRPI0819688A2 (pt)	2007-12-14	2015-06-16	Amgen Inc	Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
JP2011523853A (ja)	2008-06-03	2011-08-25	アボット・ラボラトリーズ	二重可変ドメイン免疫グロブリン及びその使用
WO2010100200A2 (en)	2009-03-05	2010-09-10	Novartis Ag	Lyophilised antibody formulation
WO2010100179A2 (en)	2009-03-05	2010-09-10	Novartis Ag	Self-forming gel system for sustained drug delivery
WO2010115932A1 (en)	2009-04-08	2010-10-14	Novartis Ag	Combination for the treatment of bone loss
WO2010130830A2 (en)	2009-05-15	2010-11-18	Ablynx N.V.	Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2012028683A1 (en)	2010-09-02	2012-03-08	Novartis Ag	Antibody gel system for sustained drug delivery
TWI636993B (zh)	2010-10-27	2018-10-01	安美基公司	Ｄｋｋ１抗體及使用方法

2008
- 2008-09-16 CL CL2008002775A patent/CL2008002775A1/es unknown
- 2008-09-17 HU HUE20174310A patent/HUE066466T2/hu unknown
- 2008-09-17 AR ARP080104044A patent/AR068471A1/es not_active Application Discontinuation
- 2008-09-17 CA CA2699905A patent/CA2699905C/en active Active
- 2008-09-17 FI FIEP20174310.1T patent/FI3725329T3/fi active
- 2008-09-17 EP EP16162068.7A patent/EP3085386B1/en not_active Revoked
- 2008-09-17 PL PL16162068T patent/PL3085386T3/pl unknown
- 2008-09-17 LT LTEP16162068.7T patent/LT3085386T/lt unknown
- 2008-09-17 PT PT161620687T patent/PT3085386T/pt unknown
- 2008-09-17 US US12/212,327 patent/US8017120B2/en active Active
- 2008-09-17 DK DK20174310.1T patent/DK3725329T3/da active
- 2008-09-17 SI SI200832137T patent/SI3085386T1/sl unknown
- 2008-09-17 EP EP23219258.3A patent/EP4335510A3/en active Pending
- 2008-09-17 PT PT88326905T patent/PT2195026E/pt unknown
- 2008-09-17 AU AU2008302313A patent/AU2008302313C1/en active Active
- 2008-09-17 PL PL12180292.0T patent/PL2556841T3/pl unknown
- 2008-09-17 EP EP20174310.1A patent/EP3725329B1/en active Active
- 2008-09-17 JP JP2010525108A patent/JP5643094B2/ja active Active
- 2008-09-17 CA CA3170836A patent/CA3170836A1/en active Pending
- 2008-09-17 TW TW104134720A patent/TWI612972B/zh active
- 2008-09-17 ES ES08832690.5T patent/ES2445792T3/es active Active
- 2008-09-17 LT LTEP20174310.1T patent/LT3725329T/lt unknown
- 2008-09-17 PL PL20174310.1T patent/PL3725329T3/pl unknown
- 2008-09-17 LT LTEP12180292.0T patent/LT2556841T/lt unknown
- 2008-09-17 EP EP08832690.5A patent/EP2195026B1/en active Active
- 2008-09-17 SI SI200831170T patent/SI2195026T1/sl unknown
- 2008-09-17 SI SI200831663A patent/SI2556841T1/sl unknown
- 2008-09-17 ES ES12180292.0T patent/ES2581754T3/es active Active
- 2008-09-17 ES ES16162068T patent/ES2815677T3/es active Active
- 2008-09-17 ES ES20174310T patent/ES2975587T3/es active Active
- 2008-09-17 HR HRP20240493TT patent/HRP20240493T3/hr unknown
- 2008-09-17 DK DK08832690.5T patent/DK2195026T3/da active
- 2008-09-17 PT PT201743101T patent/PT3725329T/pt unknown
- 2008-09-17 EP EP12180292.0A patent/EP2556841B9/en not_active Revoked
- 2008-09-17 TW TW097135666A patent/TWI526222B/zh active
- 2008-09-17 HU HUE12180292A patent/HUE030168T2/en unknown
- 2008-09-17 PT PT121802920T patent/PT2556841T/pt unknown
- 2008-09-17 DK DK12180292.0T patent/DK2556841T3/en active
- 2008-09-17 HU HUE16162068A patent/HUE050653T2/hu unknown
- 2008-09-17 WO PCT/US2008/076679 patent/WO2009039175A2/en active Application Filing
- 2008-09-17 DK DK16162068.7T patent/DK3085386T3/da active
- 2008-09-17 SI SI200832217T patent/SI3725329T1/sl unknown
- 2008-09-17 MX MX2010002971A patent/MX2010002971A/es active IP Right Grant
- 2008-09-17 PL PL08832690T patent/PL2195026T3/pl unknown
2011
- 2011-04-19 US US13/090,075 patent/US8440193B2/en active Active
- 2011-04-19 US US13/090,058 patent/US8329176B2/en active Active
2013
- 2013-04-11 US US13/860,954 patent/US9089553B2/en active Active
- 2013-08-12 HK HK13109416.2A patent/HK1182017A1/zh unknown
2014
- 2014-02-18 HR HRP20140153AT patent/HRP20140153T1/hr unknown
- 2014-03-07 CY CY20141100183T patent/CY1114961T1/el unknown
- 2014-09-03 JP JP2014178609A patent/JP5764704B2/ja active Active
2015
- 2015-06-16 US US14/740,838 patent/US10273293B2/en active Active
2016
- 2016-07-14 HR HRP20160872TT patent/HRP20160872T1/hr unknown
- 2016-07-15 CY CY20161100685T patent/CY1117908T1/el unknown
2017
- 2017-10-27 AR ARP170103001A patent/AR109995A2/es unknown
2018
- 2018-11-14 US US16/191,068 patent/US11091537B2/en active Active
2020
- 2020-09-02 CY CY20201100823T patent/CY1123463T1/el unknown
- 2020-09-09 HR HRP20201438TT patent/HRP20201438T1/hr unknown
2021
- 2021-07-15 US US17/376,304 patent/US20210340236A1/en active Pending

Also Published As

Publication number	Publication date
US9089553B2 (en)	2015-07-28
TW201622747A (zh)	2016-07-01
TWI526222B (zh)	2016-03-21
AU2008302313B2 (en)	2013-10-31
EP3725329B1 (en)	2024-01-31
EP4335510A3 (en)	2024-06-26
JP2010539190A (ja)	2010-12-16
US20130287764A1 (en)	2013-10-31
SI2195026T1 (sl)	2014-04-30
EP3085386A1 (en)	2016-10-26
LT3725329T (lt)	2024-03-25
HRP20160872T1 (hr)	2016-09-23
CL2008002775A1 (es)	2008-11-07
US20210340236A1 (en)	2021-11-04
PL3085386T3 (pl)	2020-11-30
US10273293B2 (en)	2019-04-30
MX2010002971A (es)	2010-08-10
JP5643094B2 (ja)	2014-12-17
EP3725329A1 (en)	2020-10-21
HRP20140153T1 (hr)	2014-04-25
LT3085386T (lt)	2020-11-25
JP5764704B2 (ja)	2015-08-19
SI2556841T1 (sl)	2016-10-28
JP2015038076A (ja)	2015-02-26
EP2195026A2 (en)	2010-06-16
PT3725329T (pt)	2024-03-14
DK2195026T3 (da)	2014-03-03
US8017120B2 (en)	2011-09-13
ES2445792T3 (es)	2014-03-05
EP2195026B1 (en)	2013-12-25
DK3085386T3 (da)	2020-09-28
EP2556841B9 (en)	2017-09-06
US20090074763A1 (en)	2009-03-19
HUE050653T2 (hu)	2020-12-28
US20150274817A1 (en)	2015-10-01
CY1123463T1 (el)	2022-03-24
US20110268730A1 (en)	2011-11-03
PL3725329T3 (pl)	2024-06-10
US8329176B2 (en)	2012-12-11
TWI612972B (zh)	2018-02-01
US11091537B2 (en)	2021-08-17
HRP20240493T3 (hr)	2024-07-05
CA3170836A1 (en)	2009-03-26
PT2556841T (pt)	2016-07-25
EP4335510A2 (en)	2024-03-13
DK2556841T3 (en)	2016-08-15
DK3725329T3 (da)	2024-03-18
EP2556841B1 (en)	2016-05-11
HK1182017A1 (zh)	2013-11-22
AU2008302313A1 (en)	2009-03-26
PT3085386T (pt)	2020-09-15
WO2009039175A3 (en)	2009-05-07
CY1117908T1 (el)	2017-05-17
EP3085386B1 (en)	2020-06-24
SI3725329T1 (sl)	2024-04-30
HUE066466T2 (hu)	2024-08-28
US20110262433A1 (en)	2011-10-27
LT2556841T (lt)	2016-09-12
CY1114961T1 (el)	2016-12-14
HRP20201438T1 (hr)	2020-11-27
AU2008302313C1 (en)	2014-04-03
HUE030168T2 (en)	2017-05-29
PT2195026E (pt)	2014-03-31
CA2699905A1 (en)	2009-03-26
WO2009039175A2 (en)	2009-03-26
US8440193B2 (en)	2013-05-14
CA2699905C (en)	2023-09-05
US20190100580A1 (en)	2019-04-04
AR109995A2 (es)	2019-02-13
AR068471A1 (es)	2009-11-18
PL2195026T3 (pl)	2014-05-30
ES2581754T3 (es)	2016-09-07
FI3725329T3 (fi)	2024-03-18
PL2556841T3 (pl)	2016-11-30
ES2815677T3 (es)	2021-03-30
ES2975587T3 (es)	2024-07-09
TW200930403A (en)	2009-07-16
EP2556841A1 (en)	2013-02-13

Publication	Publication Date	Title
HK1182017A1 (zh)	2013-11-22	抑制骨吸收的方法
EP2367489A4 (en)	2013-05-29	CERCLAGE SYSTEM FOR BONE
IL198649A0 (en)	2010-02-17	Interspinous implant
EP2094350A4 (en)	2010-07-14	GROUPED ELECTRODES FOR BACKMARK STIMULATION
EP2079414A4 (en)	2011-12-28	SYSTEM FOR CHEMOHYPER THERMAL TREATMENT
IL211523B (en)	2018-04-30	Devices for increasing the density of jaw-skull bones
GB0707096D0 (en)	2007-05-23	Method
EP2171169A4 (en)	2013-07-31	METHOD
EP2194893A4 (en)	2014-08-06	IMPLANT SYSTEM
PL2002702T3 (pl)	2016-05-31	Sposób wstępnego kiełkowania materiału siewnego
GB0703366D0 (en)	2007-03-28	Method
GB2456999B (en)	2011-04-27	Method for preparing 2-deoxy-L-ribose
EP2058409A4 (en)	2012-12-12	HEAT TREATMENT PROCESS
GB0600228D0 (en)	2006-02-15	Inactivation method
IL202261A0 (en)	2010-06-16	Method for pain control
GB0705321D0 (en)	2007-04-25	Method
EP2208733A4 (en)	2014-08-06	FOOD FOR INHIBITING BONE RESORPTION
ZA201002110B (en)	2010-11-24	Method for stabilizing quercetin
ZA200903242B (en)	2010-08-25	Treatment for multiple myeloma
PL1842931T3 (pl)	2014-07-31	Sposób obróbki cieplnej
GB0706833D0 (en)	2007-05-16	Method
HUP0800040A2 (en)	2009-06-29	Set for fixing bones
PL381143A1 (pl)	2008-05-26	Sposób otrzymywania 2-metyloglicydolu
GB0624469D0 (en)	2007-01-17	Cryptographically secure method
HU0700132V0 (en)	2007-09-28	Implantation for fixing bones